SynthesisWorld journal of surgical oncology2022
Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
Synthesis in World journal of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Prognostic role of statins in colorectal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Survival Difference of Endometrial Cancer Patients with Peritoneal Metastasis Receiving Cytoreductive Surgery (CRS) with and without Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- Repeat cytoreductive surgery with HIPEC for colorectal peritoneal metastases: a systematic review.World journal of surgical oncology · 2024Pooled it
- Opening the operating theatre to oncology: treatment of locally recurrent rectal cancer with peritoneal metastasis by simultaneous hyperthermic intraperitoneal chemotherapy and intraoperative electron beam radiotherapy.Annals of the Royal College of Surgeons of England · 2026Article
- Intraductal papillary mucinous neoplasm with pseudomyxoma peritonei: a case report.International journal of surgery case reports · 2026Article
- Quality of Life and Minimal Clinically Important Difference in Colorectal Cancer Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy: A Large Prospective Cohort Study.Annals of surgical oncology · 2025Article
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS + HIPEC): an initial experience at a Tertiary care Hospital in Pakistan.Pakistan journal of medical sciences · 2025Article
- Perioperative approach to nephrotoxicity in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.World journal of gastrointestinal surgery · 2025Article
- Cholinergic Receptor Nicotinic Beta 2 Subunit Promotes the Peritoneal Disseminating Metastasis of Colorectal Cancer.Cancers · 2025Article
- Strategies for the comprehensive treatment of gastric cancer ovarian metastasis.World journal of clinical oncology · 2025Review
- Expert consensus on the optimal management of BRAFAsia-Pacific journal of clinical oncology · 2025Article
- Diffuse malignant peritoneal mesothelioma: A review.Frontiers in surgery · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeritoneal metastasis often occurs in patients with colorectal cancer peritoneal metastasis, and the prognosis is poor. A large body of evidence highlights the beneficial effects of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on survival, but to date, there is little consensus on the optimal treatment strategy for patients with colorectal cancer peritoneal metastasis. The purpose of this study is to evaluate the impact of CRS + HIPEC on survival and provide reference for the treatment of patients with colorectal cancer peritoneal metastasis.
methodsThis systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The PubMed, Embase, Cochrane, Web of Knowledge, and ClinicalTrials.gov databases were screened from inception of the review to March 11, 2022. Ten studies were included in qualitative and quantitative analysis.
resultsA total of 3200 patients were enrolled in the study, including 788 patients in the CRS and HIPEC groups and 2412 patients in the control group, of which 3 were randomized controlled trials and 7 were cohort studies. The 3 randomized controlled studies were of high quality, and the quality scores of the 7 cohort studies were all 7 or above, indicating high quality. The results showed that the OS of CRS + HIPEC group was higher than that of control group (HR: 0.53, 95% CI: 0.38-0.73; P < 0.00001, I
conclusionsCRS + HIPEC can improve the survival rate of patients with colorectal cancer peritoneal metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.